ENDRA Life Sciences Inc. (NDRA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. ENDRA Life Sciences Inc. is a biotechnology company developing a Thermo-Acoustic Enhanced Ultrasound (TAEUS) medical device for liver fat measurement and metabolic disease management. In 2025, the Company adopted a Digital Asset Treasury (DAT) strategy, allocating treasury reserves to cryptocurrency (specifically HYPE tokens) alongside its core medical device operations. The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,595,959) | $(2,354,090) | $(3,858,201) | $(7,358,943) |
| Net Loss Per Share (Basic/Diluted) | $(2.10) | $(9.54) | $(5.68) | $(82.14) |
| Cash and Cash Equivalents (End of Period) | $794,036 | $4,745,187 | $794,036 | $4,745,187 |
| Working Capital | $248,402 | $2,828,435 | $248,402 | $2,828,435 |
| Total Assets | $1,964,108 | $4,452,362 | $1,964,108 | $4,452,362 |
| Accumulated Deficit | $(107,296,300) | $(99,289,095) | $(107,296,300) | $(99,289,095) |
Operating Expenses (YTD 2025 vs YTD 2024):
- Research & Development: $1,341,859 (Decrease of 47%)
- Sales & Marketing: $183,110 (Decrease of 62%)
- General & Administrative: $2,616,106 (Decrease of 25%)
Liquidity & Debt: The Company holds no long-term debt other than lease liabilities ($525,328 total). A warrant liability of $595,884 is recorded on the balance sheet.
Material Changes vs. Prior Period
- Reduced Burn Rate: Net loss decreased significantly year-over-year (47% reduction for the nine months ended Sept 30, 2025) due to reduced R&D and S&M spending following a restructuring in Q2 2024.
- Cash Position: Cash reserves declined from $3.23 million at year-end 2024 to $794,036 at Sept 30, 2025, driven by operating cash outflows of $3.57 million for the nine-month period.
- Warrant Liability Volatility: The Company recognized a gain of $203,400 from changes in the fair value of warrant liability for the nine months ended Sept 30, 2025, compared to a loss of $3.34 million in the prior year period.
- Stock Structure: The Company executed two reverse stock splits in 2024 (1-for-50 and 1-for-35) to regain Nasdaq compliance. All share data in this filing is retroactively restated.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: Management continues to focus on the commercialization of the TAEUS device and the execution of the DAT strategy. The Company expects to incur significant expenses and operating losses for the foreseeable future. No revenue has been generated to date.
Subsequent Events (Post-Sept 30, 2025):
- Private Placement: On Oct 15, 2025, the Company closed a private placement raising approximately $4.9 million. The majority of proceeds were used to purchase ~78,863 HYPE tokens (valued at ~$3.0 million) for the DAT strategy. Up to $750,000 is allocated for a pilot validation imaging study.
- New ATM Agreement: On Oct 29, 2025, the Company entered a new At-The-Market (ATM) agreement with Lucid Capital Markets to sell up to $1.75 million of common stock.
Risks and Contingencies:
- Going Concern: The filing includes a substantial doubt disclosure regarding the Company's ability to continue as a going concern without additional financing. Cash on hand ($794k) is insufficient to fund operations for the next 12 months.
- Nasdaq Compliance: The Company received notice in May 2025 of non-compliance with the $2.5 million stockholders' equity requirement. Management believes the Oct 2025 private placement has restored compliance, but Nasdaq will continue to monitor.
- Cryptocurrency Risks: Significant risks exist regarding the classification of digital assets as securities (potential 1940 Act registration), price volatility, and cybersecurity threats to custodial holdings.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of Sept 30, 2025, citing a material weakness due to insufficient accounting personnel to segregate duties.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $794k cash balance against current burn rates and the timeline for the pilot study funding.
- DAT Strategy Execution: Confirm the valuation and custody details of the HYPE tokens purchased in October 2025 and the impact of ASU 2023-08 (fair value accounting) on future earnings volatility.
- Nasdaq Status: Monitor subsequent filings to confirm the Company has formally regained compliance with the $2.5 million stockholders' equity requirement.
- Internal Control Remediation: Review future filings for progress on hiring accounting personnel to address the material weakness in internal controls.
- Regulatory Approval: Track progress on FDA de novo application for the TAEUS device, as commercialization and revenue generation are entirely dependent on this approval.